دورية أكاديمية
أعرض في EDS

Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol.

التفاصيل البيبلوغرافية
العنوان: Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol.
المؤلفون: van der Ploeg P; Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., Hendrikse CS; Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., Thijs AM; Department of Internal Medicine and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands., Westgeest HM; Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands., Smedts HP; Department of Obstetrics and Gynaecology, Amphia Hospital, Breda, the Netherlands., Vos MC; Department of Obstetrics and Gynaecology, Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands., Jalving M; Department of Medical Oncology, University Medical Centre Groningen, Groningen, the Netherlands., Lok CA; Department of Gynaecologic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Boere IA; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands., van Ham MA; Department of Obstetrics and Gynaecology, Radboud University Medical Centre, Nijmegen, the Netherlands., Ottevanger PB; Department of Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands., Westermann AM; Department of Oncology, Amsterdam University Medical Centre, Amsterdam, the Netherlands., Mom CH; Department of Obstetrics and Gynaecology, Amsterdam University Medical Centre, Amsterdam, the Netherlands., Lalisang RI; Department of Medical Oncology, Maastricht University Medical Centre +, Maastricht, the Netherlands., Lambrechts S; Department of Obstetrics and Gynaecology, Maastricht University Medical Centre +, Maastricht, the Netherlands., Bekkers RL; Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., Piek JM; Department of Obstetrics and Gynaecology and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.
المصدر: Heliyon [Heliyon] 2023 Dec 01; Vol. 10 (1), pp. e23170. Date of Electronic Publication: 2023 Dec 01 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101672560 Publication Model: eCollection Cited Medium: Print ISSN: 2405-8440 (Print) Linking ISSN: 24058440 NLM ISO Abbreviation: Heliyon Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : Elsevier Ltd, [2015]-
مستخلص: Objective: Ovarian cancer is the fifth cause of cancer-related death among women. The benefit of targeted therapy for ovarian cancer patients is limited even if treatment is stratified by molecular signature. There remains a high unmet need for alternative diagnostics that better predict targeted therapy, as current diagnostics are generally inaccurate predictors. Quantitative assessment of functional signal transduction pathway (STP) activity from mRNA measurements of target genes is an alternative approach. Therefore, we aim to identify aberrantly activated STPs in tumour tissue of patients with recurrent ovarian cancer and start phenotype -guided targeted therapy to improve survival without compromising quality of life.
Study Design: Patients with recurrent ovarian cancer and either 1) have platinum-resistant disease, 2) refrain from standard therapy or 3) are asymptomatic and not yet eligible for standard therapy will be included in this multi-centre prospective cohort study with multiple stepwise executed treatment arms. Targeted therapy will be available for patients with aberrantly high functional activity of the oestrogen receptor, androgen receptor, phosphoinositide 3-kinase or Hedgehog STP. The primary endpoint of this study is the progression-free survival (PFS) ratio (PFS2/PFS1 ratio) according to RECIST 1.1 determined by the PFS on matched targeted therapy (PFS2) compared to PFS on prior therapy (PFS1). Secondary endpoints include among others best overall response, overall survival, side effects, health-related quality of life and cost-effectiveness.
Conclusion: The results of this study will show the clinical applicability of STP activity in selecting recurrent ovarian cancer patients for effective therapies.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jurgen Piek reports equipment, drugs, or supplies was provided by InnoSIGN. Phyllis van der Ploeg reports a relationship with Catharina Research Fund that includes: funding grants. Cynthia Hendrikse reports a relationship with Catharina Research Fund that includes: funding grants. Phyllis van der Ploeg reports a relationship with InnoSIGN that includes: funding grants. Cynthia Hendrikse reports a relationship with InnoSIGN that includes: funding grants.
(© 2024 The Authors. Published by Elsevier Ltd.)
References: Lancet Oncol. 2015 Oct;16(13):1324-34. (PMID: 26342236)
Cancers (Basel). 2020 Oct 27;12(11):. (PMID: 33120947)
Int J Mol Sci. 2013 Jan 09;14(1):1179-96. (PMID: 23303278)
Cancers (Basel). 2020 Sep 18;12(9):. (PMID: 32961868)
J Ovarian Res. 2014 Nov 04;7:95. (PMID: 25366565)
BMC Cancer. 2017 Jun 30;17(1):456. (PMID: 28666422)
Am J Pathol. 2018 Sep;188(9):1956-1972. (PMID: 30030980)
Cancers (Basel). 2019 May 14;11(5):. (PMID: 31091744)
Cancers (Basel). 2019 Mar 01;11(3):. (PMID: 30832253)
Cancer. 2023 May 1;129(9):1361-1371. (PMID: 36867576)
Cancer Res. 2014 Jun 1;74(11):2936-45. (PMID: 24695361)
Anticancer Res. 2014 Apr;34(4):2007-14. (PMID: 24692739)
Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:61-85. (PMID: 34669199)
Cancers (Basel). 2020 Feb 27;12(3):. (PMID: 32120793)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Mol Cancer Ther. 2020 Feb;19(2):680-689. (PMID: 31727690)
Eur J Cancer. 2018 Jan;88:31-37. (PMID: 29179135)
Oncology. 1997 May-Jun;54(3):199-202. (PMID: 9143399)
Int J Cancer. 2020 Jun 1;146(11):3196-3206. (PMID: 31745978)
Cancers (Basel). 2020 Mar 27;12(4):. (PMID: 32230714)
Cancer. 2007 Dec 1;110(11):2448-56. (PMID: 17918264)
Acta Obstet Gynecol Scand. 2022 Feb;101(2):256-264. (PMID: 34927235)
Control Clin Trials. 1989 Mar;10(1):1-10. (PMID: 2702835)
Anticancer Res. 2014 May;34(5):2481-7. (PMID: 24778064)
Cancers (Basel). 2021 Oct 12;13(20):. (PMID: 34680250)
Eur J Cancer. 1994;30A(7):911-4. (PMID: 7946581)
CA Cancer J Clin. 2020 Jan;70(1):7-30. (PMID: 31912902)
J Clin Oncol. 2010 Nov 20;28(33):4877-83. (PMID: 20921468)
Sci Rep. 2019 Feb 7;9(1):1603. (PMID: 30733525)
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. (PMID: 8433390)
BMC Cancer. 2021 May 4;21(1):499. (PMID: 33947352)
CA Cancer J Clin. 2018 Jul;68(4):284-296. (PMID: 29809280)
Cancer Discov. 2017 Jun;7(6):586-595. (PMID: 28365644)
Semin Cancer Biol. 2019 Dec;59:147-160. (PMID: 31128298)
Front Genet. 2021 Feb 05;11:598118. (PMID: 33613616)
Acta Oncol. 1995;34(6):813-20. (PMID: 7576750)
Oncology. 2004;66(2):112-7. (PMID: 15138362)
Gynecol Oncol. 2019 Feb;152(2):278-285. (PMID: 30501904)
J Clin Oncol. 2017 Apr 1;35(10):1103-1111. (PMID: 28221866)
Cancer Discov. 2016 Feb;6(2):130-2. (PMID: 26851184)
Cancers (Basel). 2020 Sep 24;12(10):. (PMID: 32987743)
Cells. 2019 Feb 19;8(2):. (PMID: 30791431)
Cancer. 2014 Nov 15;120(22):3446-56. (PMID: 24948110)
فهرسة مساهمة: Keywords: Off-label drugs; Ovarian cancer; Signal transduction pathways; Survival; targeted therapy
تواريخ الأحداث: Date Created: 20240108 Latest Revision: 20240109
رمز التحديث: 20240109
مُعرف محوري في PubMed: PMC10770441
DOI: 10.1016/j.heliyon.2023.e23170
PMID: 38187310
قاعدة البيانات: MEDLINE
الوصف
تدمد:2405-8440
DOI:10.1016/j.heliyon.2023.e23170